Nuclear magnetic resonance analysis of pharmaceuticals 1 1 Other titles in this series are: I.- J.W. Turczan and T.C. Kram, J. Pharm. Sci., 56(12), 1643-1645 (1967). II.-T.C. Kram and J.W. Turczan, J. Pharm. Sci., 57(4), 651-652 (1968). III.-T.C. Kram and J.W. Turczan, FDA By-Lines, 2(3), 105-130 (1971). IV.-J.W. Turczan and T. Medwick, J. Pharm. Sci., 61(3), 434-443 (1972). V.-J.W. Turczan and B.A. Goldwitz, J. Pharm. Sci., 61(4), 613-615 (1972). VI.-J.W. Turczan and B.A. Goldwitz, J. Pharm. Sci., 61(8), August (1972). —VII
Titel:
Nuclear magnetic resonance analysis of pharmaceuticals 1 1 Other titles in this series are: I.- J.W. Turczan and T.C. Kram, J. Pharm. Sci., 56(12), 1643-1645 (1967). II.-T.C. Kram and J.W. Turczan, J. Pharm. Sci., 57(4), 651-652 (1968). III.-T.C. Kram and J.W. Turczan, FDA By-Lines, 2(3), 105-130 (1971). IV.-J.W. Turczan and T. Medwick, J. Pharm. Sci., 61(3), 434-443 (1972). V.-J.W. Turczan and B.A. Goldwitz, J. Pharm. Sci., 61(4), 613-615 (1972). VI.-J.W. Turczan and B.A. Goldwitz, J. Pharm. Sci., 61(8), August (1972). —VII
Auteur:
Turczan, John W. Goldwitz, Bruce A. Nelson, James J.